Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287243 | 1.00 | SCN9A (0.54) | SCN9ACTSSCTSKCTSLTACR1 | |
| SCHEMBL2357912 | 0.87 | CTSS (0.58) | CTSSCTSKCTSLTACR1MAPT | |
| SCHEMBL7373169 | 0.82 | NR3C2 (0.46) | SCN9ACTSSCTSKCTSLTACR1 | |
| SCHEMBL7373170 | 0.82 | NR3C2 (0.46) | SCN9ACTSSCTSKCTSLTACR1 | |
| SCHEMBL17949554 | 0.81 | TACR1 (0.77) | SCN9ACTSSCTSKCTSLTACR1 | |
| SCHEMBL31236325 | 0.81 | TACR1 (0.77) | SCN9ACTSSCTSKCTSLTACR1 | |
| SCHEMBL2286482 | 0.79 | SCN9A (0.48) | SCN9ATACR1MAPTSMN1; SMN2NR3C2 | |
| SCHEMBL2286478 | 0.79 | SCN9A (0.48) | SCN9ATACR1MAPTSMN1; SMN2NR3C2 | |
| SCHEMBL31725808 | 0.77 | TACR1 (0.56) | SCN9ACTSSCTSKCTSLTACR1 | |
| SCHEMBL22734261 | 0.77 | ACE (0.57) | SCN9ACTSSCTSKCTSLTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | GPR119, SSTR3, SSTR2 | SCN9A 1991/4885CTSS 2611/4885CTSK 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.